Most depressed patients fail to achieve remission despite adequate antidepressant monotherapy, and a substantial minority show minimal improvement despite optimal and aggressive therapy. However, major advances have taken place in elucidating the neurobiology of depression, and several novel targets for antidepressant therapy have emerged. Three primary approaches are currently being taken: 1) optimizing the pharmacologic modulation of monoaminergic neurotransmission, 2) developing medications that target neurotransmitter systems other than the monoamines, and 3) directly modulating neuronal activity via focal brain stimulation. We review novel therapeutic targets for developing improved antidepressant therapies, including triple monoamine reuptake inhibitors, atypical antipsychotic augmentation, dopamine receptor agonists, corticotropin-releasing factor-1 receptor antagonists, glucocorticoid receptor antagonists, substance P receptor antagonists, N-methyl-D-aspartate receptor antagonists, nemifi tide, omega-3 fatty acids, and melatonin receptor agonists. Developments in therapeutic focal brain stimulation include vagus nerve stimulation, transcranial magnetic stimulation, magnetic seizure therapy, transcranial direct current stimulation, and deep brain stimulation.
Introduction
Depression is a highly prevalent and disabling condition. Available treatments lead to symptomatic improvement in most patients, although antidepressant effects typically are not fully realized for several weeks. Up to 70% of depressed patients have residual symptoms despite adequate treatment, and 20% or more may show limited response even with the most aggressive therapies. Addi-tionally, recurrent episodes are the rule rather than the exception, and few evidence-based approaches to maintaining an antidepressant response are available. Thus, improved antidepressant treatments are clearly needed.
Currently available and commonly used antidepressant treatments include various forms of psychotherapy, pharmacotherapy, and electroconvulsive therapy (ECT). Vagus nerve stimulation (VNS) recently was approved by the US Food and Drug Administration (FDA) for the adjunctive treatment of medication-refractory depression, although the Centers for Medicare and Medicaid Services and most other third party payers largely have refused to reimburse providers for this treatment. Most of these treatments were developed based on serendipitous discoveries and/or a limited understanding of the neurobiology of depression that focused almost exclusively on the monoaminergic neurotransmitter systems. As our understanding of the neuroscience of depression has advanced, several novel targets for antidepressant treatment have been identifi ed and are under active investigation. Generally, these treatments fall into three major categories: 1) medications aimed at optimizing modulation of monoaminergic neurotransmitters, 2) medications targeting other neurotransmitter and neuromodulatory systems beyond the monoamines, and 3) focal electrical brain stimulation techniques. In this review, we survey these developing treatments and highlight those that appear to hold the most promise.
Optimizing Monoaminergic Modulation
Medications that modulate monoaminergic neurotransmitter function by one mechanism or another can possess antidepressant effi cacy, as demonstrated in multiple randomized, double-blind, controlled trials. Such medications include the tricyclic/tetracyclic antidepressants (TCAs), monoamine oxidase inhibitors (MAOIs), selective serotonin (5-HT) reuptake inhibitors (SSRIs), 5-HT and norepinephrine (NE) dual-reuptake inhibitors (SNRIs), and several atypical antidepressants (eg, nefazodone, bupropion, and mirtazapine). Mechanisms of action for these medications primarily include the following: 1) inhibiting reuptake of NE and/or 5-HT into the presynaptic terminal from the synapse (TCAs, SSRIs, and SNRIs); 2) inhibiting monoamine oxidase, the enzyme that degrades 5-HT, NE, and dopamine (DA) in the presynaptic terminal (MAOIs); or 3) blocking or stimulating presynaptic and/or postsynaptic monoamine neurotransmitter receptors (mirtazapine, nefazodone, trazodone, and several atypical antipsychotics). Given these agents' success in treating many patients with depression, increasing interest and research has focused on novel ways of optimizing monoaminergic neuromodulation. In particular, efforts have targeted DA circuits based on a burgeoning database supporting a critical role for DA dysfunction in the pathophysiology of depression [1•]. Emerging treatments in this category include triple reuptake inhibitors, atypical antipsychotic augmentation, and DA receptor agonists.
Triple reuptake inhibitors
Triple reuptake inhibitors include agents designed to block synaptic reuptake of all three monoamines (5-HT, NE, and DA). Several candidates have shown antidepressant-like effects in animal studies. One compound (DOV 216303; DOV Pharmaceutical, Somerset, NJ) was found to be safe and tolerable during short-term use in an openlabel, phase 1 study [2] . Another agent, tesofensine (NS 2330; Boehringer Ingelheim, Ingelheim, Germany), has shown modest preliminary effi cacy and safety in treating motor symptoms associated with advanced Parkinson's disease [3] , but no clinical data for treating depression are available. Two major concerns in the development of DA reuptake inhibitors are drug abuse liability and autonomic side effects.
Atypical antipsychotic augmentation
Compared with older, high-potency "typical" antipsychotics (eg, haloperidol, perphenazine) that blocked DA D 2 receptor at occupancy rates of 90% or more, atypical antipsychotics (clozapine, olanzapine, risperidone, paliperidone, quetiapine, ziprasidone, and aripiprazole) exhibit occupancy rates at D 2 receptors of 70% or less. They also possess increased affi nity for several 5-HT receptors and possibly glutamate receptors; aripiprazole also functions as a partial agonist at the D 2 receptor. Antidepressant effects seen with these agents therefore may be related to DA function modulation and other potential mechanisms. Drugs in this class generally are associated with fewer extrapyramidal side effects than typical antipsychotics, but some of these have been associated with a unique and challenging set of side effects, including weight gain, glucose intolerance, and serum lipid abnormalities. Certain drugs in this class have been shown to be effective in augmenting SSRIs in certain anxiety disorders, such as obsessive-compulsive disorder [4] and post-traumatic stress disorder [5] .
Early open-label studies and retrospective case reviews suggested that atypical antipsychotics may augment the action of standard antidepressant medications, even in the absence of psychotic features in the depressive episode [6] . Aripiprazole has demonstrated antidepressant effi cacy as an augmentation treatment in patients not responding to standard antidepressant medications in two large, randomized, placebo-controlled trials [7•,8] ; in November 2007, the FDA approved aripiprazole for this indication. An olanzapine-fl uoxetine combination is FDA approved for treating bipolar depression [9] . Quetiapine monotherapy appears to be safe and effi cacious in treating bipolar depression [10,11•] , which led to FDA approval for this indication in 2006. Considerable evidence now indicates that quetiapine is effective for treating major depressive disorder alone or in combination with standard antidepressant medications [12] [13] [14] [15] . These effects of quetiapine are likely due in part to its potency as an NE reuptake inhibitor. Risperidone was effective as an adjunct in SSRI nonresponders in two randomized, double-blind, placebocontrolled trials [16, 17] .
Dopamine agonists
Pramipexole and ropinirole are DA D 2 and D 3 receptor agonists. Two placebo-controlled trials have helped to confi rm that pramipexole is safe, tolerable, and effi cacious for bipolar depression [18, 19] . An open-label study with long-term follow-up suggested that pramipexole also may be effective in treatment-resistant unipolar depression [20, 21] . Another open-label study suggested similar benefi ts for ropinirole [22] . Further investigation of these agents is under way.
Novel Pharmacologic Targets: Beyond Monoamines

Corticotropin-releasing factor-1 receptor antagonists
Increased activity of the hypothalamic-pituitary-adrenal (HPA) axis characterizes the human endocrine stress response. After a stressful stimulus, the neuropeptide corticotropin-releasing factor (CRF) is released into the hypothalamo-hypophysial portal circulation and stimulates secretion of adrenocorticotropin from the anterior pituitary. Adrenocorticotropin acts on the adrenal cortex to stimulate glucocorticoid production and release cortisol (in humans). Physical or emotional stress can precipitate or exacerbate depression in vulnerable individuals, and a growing database supports a role for the HPA axis-and specifi cally CRF-in this process. Depressed patients exhibit increased HPA axis activity and elevated cerebrospinal fl uid CRF concentrations, increased paraventricular nucleus CRF mRNA expression, and more CRF-containing neurons compared with nondepressed controls. Antidepressant treatment (with the TCA desipramine) has been associated with reduced cerebrospinal fl uid CRF concentrations in healthy volunteers, and depressed patients have shown similar changes after treatment with fl uoxetine and ECT. These data (see [23] for a comprehensive review) suggest that
